Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

DS-6157

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Daiichi Sankyo

Drug class:

Topoisomerase I inhibitor, GPR20 -targeted antibody-drug conjugate

Related drugs:

‹

irinotecan liposomal (0)

topotecan episcleral (0)

fam-trastuzumab deruxtecan-nxki (90)

irinotecan (48)

sacituzumab govitecan-hziy (17)

HRA00129-C004 (3)

nanoliposomal irinotecan (3)

camptothecin nanosomal (1)

PF-08046044 (1)

HA-irinotecan (0)

ICAM‑1 ADC (0)

etirinotecan pegol (0)

irinotecan liposomal (0)

topotecan episcleral (0)

›

KIT wild-type	Gastrointestinal Stromal Tumor	KIT wild-type	Gastrointestinal Stromal Tumor	DS-6157 Sensitive: C3 – Early Trials DS-6157 Sensitive : C3	DS-6157 Sensitive: C3 – Early Trials DS-6157 Sensitive : C3
SDHB mutation + NF1 mutation	Gastrointestinal Stromal Tumor	SDHB mutation + NF1 mutation	Gastrointestinal Stromal Tumor	DS-6157 Sensitive: C4 – Case Studies DS-6157 Sensitive : C4	DS-6157 Sensitive: C4 – Case Studies DS-6157 Sensitive : C4
GPR20 expression	Gastrointestinal Stromal Tumor	GPR20 expression	Gastrointestinal Stromal Tumor	DS-6157 Sensitive: D – Preclinical DS-6157 Sensitive : D	DS-6157 Sensitive: D – Preclinical DS-6157 Sensitive : D